<DOC>
	<DOC>NCT01136655</DOC>
	<brief_summary>This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.</brief_summary>
	<brief_title>A Study in Asthmatic Children (6 to &lt;12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy</brief_title>
	<detailed_description>A Phase 2, randomized, blinded, 5-period cross-over, placebo and active controlled, multicenter, dose-finding study comparing single doses of formoterol 2.25 µg, 4.5 µg, and 9 µg delivered via Symbicort pMDI and Foradil® 12 µg evaluating the relative bronchodilating effects and safety in children.</detailed_description>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 1 Has a FEV1 measured at least 6 hours after the last dose of inhaled, shortacting β2agonist (SABA) and at least 48 hours after the last dose of inhaled longacting β2agonist of =60% and =85% of predicted normal. Demonstrated reversibility of FEV1 of =15% from pre short acting beta agonist level within 15 to 30 minutes after administration of a standard dose of short acting beta agonist Has been hospitalized for &gt;24 hours at least once or required emergency treatment or urgent care visit more than once for an asthmarelated condition during the 6 months prior to Visit 1 Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>asthmatic children</keyword>
	<keyword>Symbicort</keyword>
	<keyword>Foradil</keyword>
</DOC>